Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia

Authors	STASIK S. ECKARDT J. N. KRAMER M. ROLLIG C. KRAMER A. SCHOLL S. HOCHHAUS A. CRYSANDT M. BRUMMENDORF T. H. NAUMANN R. STEFFEN B. KUNZMANN V. EINSELE H. SCHAICH M. BURCHERT A. NEUBAUER A. SCHAFER-ECKART K. SCHLIEMANN C. KRAUSE S. HERBST R. HANEL M. FRICKHOFEN N. NOPPENEY R. KAISER U. BALDUS C. D. KAUFMANN M. RÁČIL Zdeněk PLATZBECKER U. BERDEL W. E. MAYER Jiří SERVE H. MULLER-TIDOW C. EHNINGER G. BORNHAUSER M. SCHETELIG J. MIDDEKE J. M. THIEDE C.
Year of publication	2021
Type	Article in Periodical
Magazine / Source	BLOOD ADVANCES
MU Faculty or unit	Faculty of Medicine
Citation
Web	https://journals.sagepub.com/doi/10.1177/17534666211042529
Doi	http://dx.doi.org/10.1182/bloodadvances.2021004631
Keywords	PTPN11 mutations; cute myeloid leukemia
Description	The tyrosine-protein phosphatase nonreceptor type 11 (PTPN11) is an important regulator of RAS signaling and frequently affected by mutations in patients with acute myeloid leukemia (AML). Despite the relevance for leukemogenesis and as a potential therapeutic target, the prognostic role is controversial. To investigate the prognostic impact of PTPN11 mutations, we analyzed 1529 adult AML patients using next-generation sequencing. PTPN11 mutations were detected in 106 of 1529 (6.93%) patients (median VAF: 24%) in dominant (36%) and subclonal (64%) configuration. Patients with PTPN11 mutations were associated with concomitant mutations in NPM1 (63%), DNMT3A (37%), and NRAS (21%) and had a higher rate of European LeukemiaNet (ELN) favorable cytogenetics (57.8% vs 39.1%; P < .001) and higher white blood cell counts (P = .007) compared with PTPN11 wild-type patients. In a multivariable analysis, PTPN11 mutations were independently associated with poor overall survival (hazard ratio [HR]: 1.75; P < .001), relapse-free survival (HR: 1.52; P = .013), and a lower rate of complete remission (odds ratio: 0.46; P = .008). Importantly, the deleterious effect of PTPN11 mutations was confined predominantly to the ELN favorable-risk group and patients with subclonal PTPN11 mutations (HR: 2.28; P < .001) but not found with dominant PTPN11 mutations (HR: 1.07; P = .775), presumably because of significant differences within the rate and spectrum of associated comutations. In conclusion, our data suggest an overall poor prognostic impact of PTPN11 mutations in AML, which is significantly modified by the underlying cytogenetics and the clonal context in which they occur.